title: Specificity, stability, and potency of monocyclic beta-lactam inhibitors of human leucocyte elastase.
abstract: Stable, potent, highly specific, time-dependent monocyclic beta-lactam inhibitors of human leucocyte elastase (HLE) are described. The heavily substituted beta-lactams are stable under physiological conditions including in the presence of enzymes of the digestive tract. The beta-lactams were unstable in base. At pH 11.3 and 37 degrees C they were hydrolyzed with half-lives of 1.5-2 h. Hydrolysis produced characteristic products including the substituent originally at C-4 of the lactam ring, a substituted urea, and products resulting from decarboxylation of the acid after ring opening. The most potent beta-lactam displayed only 2-fold less activity versus HLE than alpha 1PI, the natural proteinaceous inhibitor. The compounds were more potent against the human and primate PMN elastases than versus either the dog or rat enzymes. Differences in the structure-activity relationships of the human versus the rat enzymes suggest significant differences between these two functionally similar enzymes. The specificity of these compounds toward HLE versus porcine pancreatic elastase (PPE) is consistent with the differences in substrate specificity reported for these enzymes [Zimmerman & Ashe (1977) Biochim. Biophys. Acta 480, 241-245]. These differences suggest that the alkyl substitutions at C-3 of the lactam ring bind in the S1 specificity pocket of these enzymes. The dependence of the stereochemistry at C-4 suggests additional differences between HLE and PPE. Most of the compounds do not inhibit other esterases or human proteases. Weak, time-dependent inhibition of human cathepsin G and alpha-chymotrypsin by one compound suggested a binding mode to these enzymes that places the N-1 substitution in the S1 pocket.
authors.affiliation: Department of Enzymology, Medicinal Chemistry Research, Merck Sharp & Dohme Research Laboratory, Rahway, New Jersey 07065.
authors.forename: W B
authors.initials: WB
authors.lastname: Knight
authors.forename: B G
authors.initials: BG
authors.lastname: Green
authors.forename: R M
authors.initials: RM
authors.lastname: Chabin
authors.forename: P
authors.initials: P
authors.lastname: Gale
authors.forename: A L
authors.initials: AL
authors.lastname: Maycock
authors.forename: H
authors.initials: H
authors.lastname: Weston
authors.forename: D W
authors.initials: DW
authors.lastname: Kuo
authors.forename: W M
authors.initials: WM
authors.lastname: Westler
authors.forename: C P
authors.initials: CP
authors.lastname: Dorn
authors.forename: P E
authors.initials: PE
authors.lastname: Finke
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000494:pharmacology*; D002918:Chymotrypsin / Q000737:chemistry; D004355:Drug Stability; D006801:Humans; D007700:Kinetics; D019272:Leukocyte Elastase; D008433:Mathematics; D008958:Models, Molecular; D015394:Molecular Structure; D009504:Neutrophils / Q000201:enzymology; D010179:Pancreas / Q000201:enzymology; D010196:Pancreatic Elastase / Q000037:antagonists & inhibitors*; D011487:Protein Conformation; D013329:Structure-Activity Relationship; D047090:beta-Lactams
chemical_list: D000900:Anti-Bacterial Agents; D047090:beta-Lactams; D002918:Chymotrypsin; D010196:Pancreatic Elastase; D019272:Leukocyte Elastase